Literature DB >> 17684638

Nosocomial bloodstream infections: organisms, risk factors and resistant phenotypes in the Brazilian University Hospital.

Rosineide M Ribas1, Claudete Freitas, Paulo P Gontijo Filho.   

Abstract

Bacteremia is one of the most frequent and challenging hospital-acquired infection and it is associated with high attributable morbidity and mortality and additional use of healthcare resources. The objective of this work was to determine the frequencies of its occurrence, organisms and resistance phenotypes associated to nosocomial acquired bloodstream infections. A total number of 51 nosocomial bacteremia by Gram-negative and 99 by Gram-positive were evaluated and compared during a 15-month period. The risk factors associated with these bacteremias were analyzed and antibiotic use and surgery were associated with bacteremia by Gram-negative and > 2 invasive devices with Gram-positive. The resistance phenotypes ESBL (extended-spectrum beta-lactamases) (23.5%) and AmpC/others (17.6%) correspond to 41.2 % with predominance of E. agglomerans among AmpC (44.4%) and K. pneumoniae among ESBLs (38.5%). Among S. aureus bacteremia, approximately 40% were associated to MRSA (methicillin-resistant Staphylococcus aureus).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684638     DOI: 10.1590/s1413-86702007000300010

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  2 in total

1.  Staphylococcal blood stream infections: epidemiology, resistance pattern and outcome at a level 1 Indian trauma care center.

Authors:  Vibhor Tak; Purva Mathur; Sanjeev Lalwani; Mahesh Chandra Misra
Journal:  J Lab Physicians       Date:  2013-01

2.  Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles.

Authors:  Jorge Alberto Cortes; Aura Lucía Leal; Anita María Montañez; Giancarlo Buitrago; Juan Sebastián Castillo; Lucy Guzman
Journal:  Braz J Infect Dis       Date:  2013-05-14       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.